


## LEGEND-T2DM Evidence Dissemination Summary

Target: **semaglutide**, Comparator: **canagliflozin** Outcome: **Joint pain** Subgroup: **All**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Nr. of outcomes	IR (/1,000 PY)
CCAE	13,515	7,206	84	11.66
Clinformatics	8,748	4,317	61	14.13
DA Germany	-	-	-	-
LDP France	-	-	-	-
MDCD	-	-	-	-
MDCR	1,029	404	<5	<12.36
Open Claims	147,657	71,797	497	6.92
Optum EHR	0	0	0	NaN
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

